Subtopic Deep Dive
CFTR Modulator Therapies
Research Guide
What is CFTR Modulator Therapies?
CFTR modulator therapies are small-molecule drugs that correct or potentiate CFTR protein function to treat cystic fibrosis in patients with specific mutations.
Potentiators like ivacaftor enhance channel gating for gating mutations such as G551D (Ramsey et al., 2011, 2140 citations). Correctors like lumacaftor and tezacaftor improve folding and trafficking of F508del-CFTR (Wainwright et al., 2015, 1601 citations). Triple combinations such as elexacaftor-tezacaftor-ivacaftor extend efficacy to single Phe508del alleles (Middleton et al., 2019, 1980 citations). Over 10 key papers from 1990-2019 document clinical outcomes.
Why It Matters
CFTR modulators transform cystic fibrosis from fatal to manageable by improving lung function, reducing exacerbations, and increasing weight in G551D patients (Ramsey et al., 2011). Lumacaftor-ivacaftor benefits homozygous F508del patients, addressing 45% of cases (Wainwright et al., 2015). Elexacaftor-tezacaftor-ivacaftor treats 90% of patients with one Phe508del allele, enabling precision medicine (Middleton et al., 2019). These therapies extend life expectancy and reduce hospitalization rates worldwide.
Key Research Challenges
Limited Mutation Coverage
Most modulators target F508del or G551D, leaving rare mutations untreated (Jennings et al., 2014). Triple combinations cover 90% but exclude nonsense mutations. Developing broad-spectrum correctors remains critical.
Protein Misfolding Persistence
F508del-CFTR forms aggresomes despite correctors, impairing trafficking (Johnston et al., 1998). Cheng et al. (1990) showed defective processing as core defect. Enhanced clearance mechanisms are needed.
Long-term Safety Issues
Clinical trials report sustained benefits but monitor liver toxicity and drug interactions (Ramsey et al., 2011). Jennings et al. (2014) highlight emerging challenges in chronic use. Real-world adherence data gaps persist.
Essential Papers
Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis
Laurent Meijer, Deborah J. Nelson, Vladimir Riazanski et al. · 2016 · Journal of Innate Immunity · 5.0K citations
(R)-Roscovitine, a pharmacological inhibitor of kinases, is currently in phase II clinical trial as a drug candidate for the treatment of cancers, Cushing's disease and rheumatoid arthritis. We her...
Update on Key Emerging Challenges in Cystic Fibrosis
Mark T. Jennings, Kristin A. Riekert, Michael Boyle · 2014 · Medical Principles and Practice · 3.7K citations
Cystic fibrosis (CF) is a multisystem disease causing severe chronic sinopulmonary disease and loss of pancreatic exocrine function, which affects approximately 70,000 individuals worldwide. New th...
A CFTR Potentiator in Patients with Cystic Fibrosis and the <i>G551D</i> Mutation
Bonnie W. Ramsey, Jane C. Davies, Noel G. McElvaney et al. · 2011 · New England Journal of Medicine · 2.1K citations
Ivacaftor was associated with improvements in lung function at 2 weeks that were sustained through 48 weeks. Substantial improvements were also observed in the risk of pulmonary exacerbations, pati...
Aggresomes: A Cellular Response to Misfolded Proteins
Jennifer Johnston, Cristina L. Ward, Ron R. Kopito · 1998 · The Journal of Cell Biology · 2.1K citations
Intracellular deposition of misfolded protein aggregates into ubiquitin-rich cytoplasmic inclusions is linked to the pathogenesis of many diseases. Why these aggregates form despite the existence o...
Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
Peter G. Middleton, Marcus Mall, Pavel Dřevı́nek et al. · 2019 · New England Journal of Medicine · 2.0K citations
Elexacaftor-tezacaftor-ivacaftor was efficacious in patients with cystic fibrosis with Phe508del-minimal function genotypes, in whom previous CFTR modulator regimens were ineffective. (Funded by Ve...
Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis
Seng H. Cheng, Richard J. Gregory, John Marshall et al. · 1990 · Cell · 1.8K citations
Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis
Ronald L. Gibson, Jane L. Burns, Bonnie W. Ramsey · 2003 · American Journal of Respiratory and Critical Care Medicine · 1.6K citations
This comprehensive State of the Art review summarizes the current published knowledge base regarding the pathophysiology and microbiology of pulmonary disease in cystic fibrosis (CF). The molecular...
Reading Guide
Foundational Papers
Start with Cheng et al. (1990, 1784 citations) for CFTR trafficking defects; Ramsey et al. (2011, 2140 citations) for ivacaftor proof-of-concept; Johnston et al. (1998, 2135 citations) for aggresome mechanisms underlying corrector needs.
Recent Advances
Study Wainwright et al. (2015, 1601 citations) for lumacaftor-ivacaftor; Middleton et al. (2019, 1980 citations) for triple therapy advances; Jennings et al. (2014, 3659 citations) for challenges.
Core Methods
High-throughput screening for correctors/potentiators; patient-derived organoids for mutation testing; FEV1, sweat chloride as trial endpoints; aggresome inhibition assays.
How PapersFlow Helps You Research CFTR Modulator Therapies
Discover & Search
Research Agent uses searchPapers('CFTR modulators F508del') to find Ramsey et al. (2011) and citationGraph to map 2140 citations linking to Wainwright et al. (2015). findSimilarPapers on Middleton et al. (2019) reveals triple therapy trials. exaSearch uncovers genotype-specific reviews like Jennings et al. (2014).
Analyze & Verify
Analysis Agent applies readPaperContent on Middleton et al. (2019) to extract FEV1 improvements, then verifyResponse with CoVe against Ramsey et al. (2011) for mutation comparisons. runPythonAnalysis plots lung function data from trials using pandas. GRADE grading scores ivacaftor evidence as high-quality from 48-week outcomes.
Synthesize & Write
Synthesis Agent detects gaps in rare mutation coverage via contradiction flagging across Cheng et al. (1990) and recent trials. Writing Agent uses latexEditText for modulator comparison tables, latexSyncCitations for 10+ papers, and latexCompile for review drafts. exportMermaid generates CFTR trafficking pathway diagrams.
Use Cases
"Compare FEV1 improvements in ivacaftor vs lumacaftor-ivacaftor trials"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas plot of Ramsey 2011 vs Wainwright 2015 data) → researcher gets overlaid bar chart of % FEV1 change.
"Draft LaTeX review section on triple CFTR modulators"
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Middleton 2019 et al.) + latexCompile → researcher gets compiled PDF with figures and references.
"Find code for CFTR folding simulations from papers"
Research Agent → paperExtractUrls (Johnston 1998) → paperFindGithubRepo → githubRepoInspect → researcher gets Python scripts modeling aggresome formation.
Automated Workflows
Deep Research workflow scans 50+ CFTR papers via searchPapers chains, producing structured reports on modulator efficacy ranked by GRADE scores. DeepScan applies 7-step analysis with CoVe checkpoints to verify F508del trial claims against Cheng et al. (1990). Theorizer generates hypotheses on next-gen correctors from aggresome data (Johnston et al., 1998).
Frequently Asked Questions
What defines CFTR modulator therapies?
CFTR modulators are drugs like potentiators (ivacaftor) and correctors (lumacaftor, tezacaftor) that restore CFTR channel function for specific mutations (Ramsey et al., 2011).
What are key methods in CFTR modulators?
Potentiators open gating-defective channels; correctors fix F508del folding and trafficking. Triple combos combine both for broader coverage (Middleton et al., 2019).
What are seminal papers on CFTR modulators?
Ramsey et al. (2011, 2140 citations) on ivacaftor; Wainwright et al. (2015, 1601 citations) on lumacaftor-ivacaftor; Middleton et al. (2019, 1980 citations) on elexacaftor-tezacaftor-ivacaftor.
What open problems exist in CFTR modulators?
Challenges include rare mutation coverage, aggresome clearance, and long-term safety beyond F508del (Jennings et al., 2014; Johnston et al., 1998).
Research Cystic Fibrosis Research Advances with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching CFTR Modulator Therapies with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Cystic Fibrosis Research Advances Research Guide